Background Type 2 diabetes mellitus (T2DM) is a condition characterized by insulin resistance and progressive failure of the insulin-secreting beta-cells. Based on studies in small cohorts of young patients (especially Pima Indian offspring), we know that individuals with childhood onset T2DM are at very high risk for diabetes-related morbidity and mortality, due to a longer life-time duration of diabetes, as well as possible faster progression of beta-cell failure. Based on the currently largest available interventional trial, the TODAY study (Treatment Options for Diabetes in Adolescents and Youth), we know that standard medical treatments (e.g., diet, exercise, metformin) are prone to fail in most patients. Our study objectives are to acquire data on the natural history of T2DM in youth. Measurements will include indices of beta-cell function, body composition, cardiovascular disease risk factors, gut hormones, adipokines, and psychological well-being. These data will be compared to findings in non-diabetic volunteers who are lean or overweight/obese. The study will also allow us to collaborate with other investigators in order to investigate factors (e.g. body composition changes, effect of life-style changes (such as sleep)) that determine the progression to and outcome of type 2 diabetes. One specific goal is to investigate the effects of a new class of drugs, sodium glucose co-transporter 2 (SGLT2) inhibitors, on bone health and to learn more about their safety profile as compared to other hypoglycemic agents. Presently we are recruiting healthy individuals in order to elucidate the underlying mechanisms of drug action on bone metabolism. In the future, we are planning to widen the spectrum of study participants and include patients with diabetes and individuals at heightened risk for bone fractures. A third objective is to continue clinical follow-up of patients who participated in Type 1 Diabetes related clinical trials (specifically: islet transplantation) conducted between 2000 and 2006. We are also analyzing and sharing stored samples (e.g., serum and plasma)in order to learn about predictors of beta cell loss.

Project Start
Project End
Budget Start
Budget End
Support Year
11
Fiscal Year
2017
Total Cost
Indirect Cost
Name
U.S. National Inst Diabetes/Digst/Kidney
Department
Type
DUNS #
City
State
Country
Zip Code
Sanchez, Gina A Montealegre; Reinhardt, Adam; Ramsey, Suzanne et al. (2018) JAK1/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies. J Clin Invest 128:3041-3052
Bauman, Viviana; Sturkey, Adaya C; Sherafat-Kazemzadeh, Rosa et al. (2018) Factitious hypoglycemia in children and adolescents with diabetes. Pediatr Diabetes 19:823-831
Blau, Jenny E; Bauman, Viviana; Conway, Ellen M et al. (2018) Canagliflozin triggers the FGF23/1,25-dihydroxyvitamin D/PTH axis in healthy volunteers in a randomized crossover study. JCI Insight 3:
Gourgari, Evgenia; Dabelea, Dana; Rother, Kristina (2017) Modifiable Risk Factors for Cardiovascular Disease in Children with Type 1 Diabetes: Can Early Intervention Prevent Future Cardiovascular Events? Curr Diab Rep 17:134
Brown, Rebecca J; Meehan, Cristina Adelia; Cochran, Elaine et al. (2017) Effects of Metreleptin in Pediatric Patients With Lipodystrophy. J Clin Endocrinol Metab 102:1511-1519
Gourgari, Evgenia A; Mete, Mihriye; Sampson, Maureen L et al. (2017) Exenatide Improves HDL Particle Counts and Size Distribution in Patients With Long-standing Type 1 Diabetes. Diabetes Care 40:e88-e89
Sylvetsky, Allison C; Issa, Najy T; Chandran, Avinash et al. (2017) Pigment Epithelium-Derived Factor Declines in Response to an Oral Glucose Load and Is Correlated with Vitamin D and BMI but Not Diabetes Status in Children and Young Adults. Horm Res Paediatr 87:301-306
Sylvetsky, Allison C; Edelstein, Sharon L; Walford, Geoffrey et al. (2017) A High-Carbohydrate, High-Fiber, Low-Fat Diet Results in Weight Loss among Adults at High Risk of Type 2 Diabetes. J Nutr 147:2060-2066
Blau, Jenny E; Tella, Sri Harsha; Taylor, Simeon I et al. (2017) Ketoacidosis associated with SGLT2 inhibitor treatment: Analysis of FAERS data. Diabetes Metab Res Rev 33:
Brown, Rebecca J; Araujo-Vilar, David; Cheung, Pik To et al. (2016) The Diagnosis and Management of Lipodystrophy Syndromes: A Multi-Society Practice Guideline. J Clin Endocrinol Metab 101:4500-4511

Showing the most recent 10 out of 42 publications